EGFR and neoplasm: Randomized phase III clinical trials have shown a survival benefit of these anti-EGFR monoclonal antibodies in RAS wild-type metastatic CRC [12-14]; however, tumor location has not traditionally been included as a stratification criterion in clinical trials.